Six patients is a deliberately small number, and that is exactly the point. Theriva Biologics has received authorization from Spain’s AEMPS to open VIRAGE2, a Phase 2a proof-of-concept trial testing whether VCN-01 (zabilugene almadenorepvec) can be dosed at least three times, spaced two months apart, in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma. The trial does not exist to prove efficacy. It exists to answer a pharmacodynamic question that regulators themselves raised: if two doses improved survival, what does more frequent dosing do to viral genome levels in blood, and can patients tolerate the regimen without triggering neutralizing antibodies that blunt the virus before it can act?
That regulatory prompting matters for understanding the trial’s design logic. The 112-patient VIRAGE Phase 2b study hit its primary endpoints of overall survival and safety, and the two-dose cohort outperformed both the single-dose arm and standard-of-care gemcitabine/nab-paclitaxel alone on OS, progression-free survival, and duration of response. Both the EMA and FDA reviewed that data and flagged the dosing interval as a variable worth pushing. VIRAGE2 is the direct response. Primary endpoints are adverse event profile and VCN-01 viral genome levels in blood, with secondary endpoints covering objective response rate, duration of response, PFS, OS, and circulating neutralizing antibody levels. The study is powered at 80% to detect a difference in viral genome levels between the first and second doses, a signal that would tell investigators whether the immune system is clearing the virus faster with each administration, which is the core feasibility risk.
VCN-01 works by selectively replicating inside tumor cells, lysing them, and degrading the hyaluronic acid-rich stroma that physically blocks chemotherapy penetration and suppresses immune infiltration in PDAC. The stroma problem is not incidental; it is a central reason why even active chemotherapy regimens, including NALIRIFOX, approved in the first-line metastatic setting based on the 770-patient NAPOLI 3 trial, produce responses that remain shallow and short. If more frequent VCN-01 dosing amplifies stromal degradation and pulls forward immune activation, the combination hypothesis with immunotherapy and KRAS inhibitors becomes substantially more testable in a pivotal setting.
The single number to watch as VIRAGE2 enrolls its six patients is the neutralizing antibody titer after the second VCN-01 dose. If anti-VCN-01 antibody levels rise sharply enough to suppress viral genomes in the third macrocycle, the more frequent dosing strategy stalls, and Theriva will need a fundamentally different approach, possibly immunosuppressive preconditioning or reformulation, before a Phase 3 design can be credibly written.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
